NASDAQ:ADXS - Advaxis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.25
  • Forecasted Upside: 435.71 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.01 (-2.33%)

This chart shows the closing price for ADXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Advaxis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADXS

Analyst Price Target is $2.25
▲ +435.71% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Advaxis in the last 3 months. The average price target is $2.25, with a high forecast of $2.25 and a low forecast of $2.25. The average price target represents a 435.71% upside from the last price of $0.42.

This chart shows the closing price for ADXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Advaxis. This rating has held steady since May 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2021Alliance Global PartnersLower Price TargetBuy$5.00 ➝ $2.25Medium
6/12/2019HC WainwrightReiterated RatingHold ➝ NeutralLow
4/5/2019HC WainwrightSet Price TargetHold$4.00Low
1/16/2019HC WainwrightReiterated RatingHoldHigh
12/18/2018HC WainwrightDowngradeBuy ➝ NeutralHigh
11/6/2018HC WainwrightSet Price TargetBuy$2.00High
9/12/2018HC WainwrightReiterated RatingBuyMedium
6/13/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$9.00 ➝ $2.00High
6/8/2018HC WainwrightReiterated RatingBuy$3.00Low
4/17/2018HC WainwrightReiterated RatingBuy$6.00High
3/14/2018HC WainwrightSet Price TargetBuy ➝ Buy$23.00 ➝ $6.00High
3/13/2018Cantor FitzgeraldLower Price TargetHold ➝ Overweight$19.00 ➝ $5.00High
12/28/2017Cantor FitzgeraldSet Price TargetBuy$19.00Low
12/27/2017HC WainwrightSet Price TargetBuy$23.00Medium
12/22/2017Cantor FitzgeraldSet Price TargetBuy$19.00Low
11/8/2017HC WainwrightReiterated RatingBuy$23.00N/A
9/25/2017Cantor FitzgeraldReiterated RatingBuy$19.00High
9/15/2017HC WainwrightReiterated RatingBuy$23.00Low
7/6/2017Cantor FitzgeraldSet Price TargetBuy$19.00Low
6/14/2017HC WainwrightSet Price TargetBuy$23.00Medium
6/12/2017Cantor FitzgeraldSet Price TargetBuy$19.00Medium
5/31/2017Cantor FitzgeraldReiterated RatingOverweight$19.00Medium
3/13/2017HC WainwrightSet Price TargetBuy$23.00Low
3/1/2017HC WainwrightReiterated RatingBuy$23.00N/A
2/27/2017Cantor FitzgeraldReiterated RatingBuy$19.00N/A
1/17/2017HC WainwrightSet Price TargetBuy$23.00N/A
11/29/2016Cantor FitzgeraldInitiated CoverageBuy$19.00N/A
10/25/2016HC WainwrightSet Price TargetBuy$23.00N/A
9/9/2016Jefferies Financial GroupReiterated RatingBuy$24.00N/A
8/25/2016Jefferies Financial GroupReiterated RatingBuyN/A
8/5/2016HC WainwrightReiterated RatingBuy$23.00N/A
8/4/2016Jefferies Financial GroupReiterated RatingBuyN/A
8/3/2016BarclaysBoost Price TargetOverweight$15.00 ➝ $20.00N/A
(Data available from 7/24/2016 forward)
Advaxis logo
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Read More

Today's Range

Now: $0.42
Low: $0.41
High: $0.44

50 Day Range

MA: $0.48
Low: $0.42
High: $0.58

52 Week Range

Now: $0.42
Low: $0.26
High: $1.57


3,303,880 shs

Average Volume

12,446,830 shs

Market Capitalization

$61.17 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Advaxis?

The following equities research analysts have issued stock ratings on Advaxis in the last twelve months: Alliance Global Partners.
View the latest analyst ratings for ADXS.

What is the current price target for Advaxis?

1 Wall Street analysts have set twelve-month price targets for Advaxis in the last year. Their average twelve-month price target is $2.25, suggesting a possible upside of 435.7%. Alliance Global Partners has the highest price target set, predicting ADXS will reach $2.25 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $2.25 for Advaxis in the next year.
View the latest price targets for ADXS.

What is the current consensus analyst rating for Advaxis?

Advaxis currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADXS will outperform the market and that investors should add to their positions of Advaxis.
View the latest ratings for ADXS.

What other companies compete with Advaxis?

How do I contact Advaxis' investor relations team?

Advaxis' physical mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company's listed phone number is 609-452-9813 and its investor relations email address is [email protected] The official website for Advaxis is